ライフサイエンスコーパス: thyroid

1 in that mediates active iodide uptake in the thyroid.

2 cell (DC) marker CD209a only in PVPV-Akt1KO thyroids.

3 n CD209a-expressing cells in the PVPV-Akt1KO thyroids.

4 toxic multinodular goiter (TMNG), and toxic thyroid adenoma (TA).

5 evels from 21 tissue datasets (brain; blood; thyroid, adrenal, and pituitary glands).

6 he liver, heart, lungs, spleen, bone marrow, thyroid and adrenal glands.

7 lity in FANTOM5 enhancers in asthma, eczema, thyroid and autoimmune disorders.

8 The patients underwent thyroid and hematologic monitoring to assess treatment e

9 ll secretory pathway and to be rearranged in thyroid and lung cancers, was strongly enriched in the p

10 tial function for asthma development in both thyroid and lung tissues.

11 and are at high risk for developing breast, thyroid and other cancers and/or autoimmunity or neurode

12 expressed in various tissues, including the thyroid and respiratory tract, and plays a crucial role

13 anatomical orientation of the rigid trachea, thyroid and the pulsating carotid artery, we hypothesize

14 of compounds' effects on estrogen, androgen, thyroid, and PPARgamma receptors of representative mamma

15 opathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is visually disabling, c

16 e thyroid storm," as defined by the Japanese Thyroid Association criteria, and at least one thyroid s

17 to (131)I therapy according to 2015 American Thyroid Association guidelines and the adverse events.

18 With preoperative MT, all American Thyroid Association intermediate, high-risk, and medulla

19 yroiditis have generally resulted in reduced thyroid autoantibody titre without apparent improvements

20 leptin maintains the hypothalamic pituitary thyroid axis, despite leptin resistance.

21 contrast-free microvascular imaging of human thyroids can be potentially beneficial in reducing the l

22 ioiodine therapy (typically mild pain in the thyroid) can be handled by nonsteroidal antiinflammatory

23 Background Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis

24 Anaplastic thyroid cancer (ATC) is one of the most aggressive human

25 all cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC), making BRAF a desirable target for

26 ve iodine ((131)I) therapy in differentiated thyroid cancer (DTC) patients requiring a completion tre

27 cific in vivo data are limited in follicular thyroid cancer (FTC), a PI3 kinase-driven tumor.

28 l involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety o

29 Papillary thyroid cancer (PTC) is the most common type of endocrin

30 lymorphisms (SNPs) associated with papillary thyroid cancer (PTC) risk.

31 ith clinically node negative (cN0) papillary thyroid cancer (PTC).

32 ing the associations of these compounds with thyroid cancer (TC) is lacking.

33 Thyroid cancer (TC) is the most frequently occurring can

34 ation was associated with increased risks of thyroid cancer [HR per 5 nmol/L higher concentration 1.1

35 ions that are improving the understanding of thyroid cancer aetiology.

36 ndicating lower thyroid function) on risk of thyroid cancer and goiter.

37 atified analyses showed an increased risk of thyroid cancer associated with the E-DII among Southern

38 nism, chemical concentrations, and papillary thyroid cancer case status.

39 d carcinomas (PTCs) account for 90% of human thyroid cancer cases, which represent 1% of all cancer c

40 n these estimated doses and the PBLS and FSS thyroid cancer cases.

41 ned activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggr

42 Thyroid cancer development and local invasion were delay

43 repair genes were associated with subsequent thyroid cancer for those treated with neck RT >= 30 Gy (

44 An increased incidence of thyroid cancer has been reported in the area close to Mo

45 missions from the volcano is associated with thyroid cancer in 186 municipalities from three province

46 iodine ((131)I) therapy may be used to treat thyroid cancer in end-stage renal disease patients who u

47 atment of metastatic melanoma and anaplastic thyroid cancer in patients with confirmed BRAF(V600E)/K

48 archipelago with one of the highest recorded thyroid cancer incidence rates in the world.

49 he global age-standardized incidence rate of thyroid cancer increased by 20%.

50 f the remaining undiscovered genetic risk in thyroid cancer is due to rare, moderate- to high-penetra

51 The incidence of thyroid cancer is on the rise, and this disease is proje

52 is not clear whether active surveillance for thyroid cancer is widely used.

53 Surgeons and endocrinologists identified by thyroid cancer patients from the Surveillance, Epidemiol

54 regarding hospital release of differentiated thyroid cancer patients treated with (131)I since the pu

55 taining clinical features from de-identified thyroid cancer patients.

56 ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored.

57 ed A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as

58 South-East was associated with a decrease in thyroid cancer rates in the whole population (- 0.67 cas

59 mined the association between differentiated thyroid cancer risk and the energy-adjusted Dietary Infl

60 Positive associations between E-DII and thyroid cancer risk were observed (comparing extreme ter

61 ed to approximately 25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc., and was ava

62 ) knock-in (PV) mice that develop metastatic thyroid cancer that most closely resembles FTC.

63 in thyroid physiology and radioiodide-based thyroid cancer treatment, also transports the environmen

64 y of core-needle biopsy for the diagnosis of thyroid cancer was low (42.8%) because the technique was

65 In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetani

66 enrolled patients with RET-mutant medullary thyroid cancer who had previously received vandetanib, c

67 ade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or c

68 is work details our experience with treating thyroid cancer with iodine in chronic renal failure pati

69 ion analysis on 2003-2016 incidence rates of thyroid cancer, adjusting for distance from Mount Etna,

70 Conclusion: In hemodialysis patients with thyroid cancer, an (131)I activity approximately 30% low

71 are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms g

72 Conclusion In a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% +/- 88 great

73 of hypothyroidism and decreases the risk of thyroid cancer, lymphoma, and a range of proliferative c

74 se domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple

75 Adjuncts and Approaches Laryngology Familial Thyroid Cancer, Postoperative Care and Complications, Ca

76 ches to Thyroidectomy, Laryngology, Familial Thyroid Cancer, Postoperative Care and Complications, Ca

77 with previously treated RET fusion-positive thyroid cancer, the percentage who had a response was 79

78 CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreat

79 ress the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1.

80 s in ablative radioiodine (RAI) treatment of thyroid cancer, where its ability to transport radioisot

81 sible increase in the incidence of childhood thyroid cancer.

82 Mount Etna in determining the high rates of thyroid cancer.

83 oaches, and the future of immunotherapies in thyroid cancer.

84 and metastatic progression in this model of thyroid cancer.

85 e-based therapies for patients with advanced thyroid cancer.

86 g the worldwide increase in the incidence of thyroid cancer.

87 dine effectiveness in radioiodine-refractory thyroid cancer.

88 ss aggressive and more common differentiated thyroid cancer.

89 editing as a potential therapeutic target in thyroid cancer.

90 e of and barriers to active surveillance for thyroid cancer.

91 are at increased risk for the development of thyroid cancer.

92 oplasia type 2 as well as sporadic medullary thyroid cancer.

93 ipating in a case-control study on papillary thyroid cancer.

94 umors, including MNG, schwannomas, papillary thyroid cancers (PTCs), and Wilms tumors.

95 ssion was particularly induced in aggressive thyroid cancers and in patients who had poorer outcomes

96 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor ty

97 rly data are now accumulating in progressive thyroid cancers treated with single-agent ICB therapies

98 nase inhibitors are effective treatments for thyroid cancers, acting primarily as antiangiogenic agen

99 RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other t

100 AF in patients with medullary and anaplastic thyroid cancers, respectively.

101 markedly enriched in kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the a

102 In patients with RET-altered thyroid cancers, the efficacy and safety of selective RE

103 current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based app

104 n; ETV1 in prostate; and IGF2BP3 and SIX2 in thyroid cancers.

105 ncers, and RET fusions occur rarely in other thyroid cancers.

106 reatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge.

107 who received radioiodine for differentiated thyroid carcinoma also showed interstitial pneumonia on

108 ocally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study.

109 Anaplastic thyroid carcinoma is an aggressive malignancy that is al

110 fforts, current knowledge of the etiology of thyroid carcinoma remains limited.

111 l trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.

112 tatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a hum

113 moking)-is associated with increased risk of thyroid carcinoma.

114 Papillary thyroid carcinomas (PTCs) account for 90% of human thyro

115 /cm pk-pk and applied them to exemplar human thyroid cell cultures for 72 h.

116 T fusion which transforms immortalized human thyroid cells in a kinase-dependent manner.

117 ine conditioned medium (CM) or with a normal thyroid CM as control.

118 NET release, whereas papillary TC or normal thyroid CM did not.

119 Surgical management of thyroid disease has evolved considerably over several de

120 pertension, elderly, systolic heart failure, thyroid disease), and CHA(2)DS(2)-VASc.

121 ity, osteoporosis, atlantoaxial instability, thyroid disease, and celiac disease.

122 ch as inflammatory bowel disease, autoimmune thyroid disease, type 1 diabetes mellitus (T1D), and aut

123 icians in the optimal surgical management of thyroid disease.

124 018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines.

125 018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines.

126 cts of cardiomyopathy, hearing loss, stroke, thyroid disorders, and diabetes were observed from the m

127 Benign thyroid disorders, especially hyper- and hypothyroidism,

128 Epidemiological studies have indicated the thyroid-disrupting effects of persistent organic polluta

129 t be an appropriate specimen to evaluate the thyroid disruption of POPs.

130 However, motion incurred by thyroid due to its proximity to the pulsating carotid ar

131 demonstrated that motion associated with the thyroid due to the carotid artery was primarily in the l

132 examine the association between subclinical thyroid dysfunction and depressive symptoms in all prosp

133 cting on the association between subclinical thyroid dysfunction and depressive symptoms.

134 lly relevant association between subclinical thyroid dysfunction at baseline and depressive symptoms

135 uctive thyroiditis (e.g., amiodarone-induced thyroid dysfunction) and factitious hyperthyroidism.

136 with the traditional notion that subclinical thyroid dysfunction, and subclinical hypothyroidism in p

137 Clinical diagnoses included thyroid eye disease (TED) (41 scans, 31 patients), non-s

138 Thyroid eye disease (TED) affects 25-50% of patients wit

139 nter trial, we assigned patients with active thyroid eye disease in a 1:1 ratio to receive intravenou

140 Thyroid eye disease is a debilitating, disfiguring, and

141 Graves orbitopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, i

142 Among patients with active thyroid eye disease, teprotumumab resulted in better out

143 fe and eye involvement in patients with mild thyroid eye disease.

144 s using mass spectrometry, and biomarkers of thyroid function [thyroid-stimulating hormone (TSH), fre

145 derived factor scores in quintiles and serum thyroid function and autoimmunity, adjusting for age, bo

146 icient pregnant women on maternal and infant thyroid function and child cognition, we aimed to determ

147 tropic effects of TSH-associated variants on thyroid function and growth of malignant and benign thyr

148 Ser1067 in DUOX2 (dual oxidase 2, related to thyroid function and innate immunity) genes and, in the

149 nversely associated with serum biomarkers of thyroid function but not with autoimmunity, which were w

150 ffect of higher TSH levels (indicating lower thyroid function) on risk of thyroid cancer and goiter.

151 between the FR levels in wristbands and the thyroid function.

152 highest SUV(max) and SUV(mean) being in the thyroid gland (30.3 +/- 2.2 and 22.5 +/- 1.6, respective

153 ly denotes disorders involving a hyperactive thyroid gland (Graves disease, toxic multinodular goiter

154 ive thyroid hormone secretion, releasing the thyroid gland from pituitary control.

155 chanism could prevent chronic stimulation of thyroid gland function.

156 ow that calcitonin, a hormone product of the thyroid gland involved in bone metabolism(3), is also pr

157 hyroidism is a common condition in which the thyroid gland provides insufficient amounts of thyroid h

158 Hormone synthesis from TG occurs in the thyroid gland via the iodination and coupling of pairs o

159 f perivascular cells in pancreas, testis and thyroid gland, with age in mice and humans.

160 tology, or expression of marker genes of the thyroid gland.

161 cal lesions in other organs, like breast and thyroid gland.

162 utoimmune disease that primarily affects the thyroid gland.

163 We have previously shown that exogenous thyroid hormone (T3) stimulates cardiomyocyte proliferat

164 e AOPs help to establish links between these thyroid hormone (TH) disrupting molecular events and adv

165 Forkhead box O (FoxO) proteins and thyroid hormone (TH) have well established roles in card

166 Thyroid hormone (TH) signaling plays an important role i

167 ganic contaminants that can compete with the thyroid hormone (TH) thyroxine (T4) for binding to trans

168 that control the concentration of the active thyroid hormone (TH) triiodothyronine through regioselec

169 tered thyroid status and mutations affecting thyroid hormone action, suggesting that these critical p

170 cts such as hypertriglyceridemia and altered thyroid hormone axis.

171 nd plays a crucial role in processes such as thyroid hormone biosynthesis and innate host defense.

172 equired for iodide uptake, which facilitates thyroid hormone biosynthesis.

173 Thyroid hormone deficiency causes delayed craniofacial a

174 Fetal thyroid hormone deficiency reduced oxidative phosphoryla

175 rapid ossification and hypertrophy; second, thyroid hormone directly affects hypochord formation and

176 and the hazard and risk assessment of these thyroid hormone disrupting chemicals.

177 a tiered screening and testing approach for thyroid hormone disruption, using the levels of assessme

178 ice that were developmentally overexposed to thyroid hormone due to a Dio3 mutation.

179 Thyroid hormone excess, by contrast, accelerates develop

180 yroid gland provides insufficient amounts of thyroid hormone for the needs of peripheral tissues.

181 transport and intracellular pH regulation to thyroid hormone homeostasis.

182 ion is also required for the biosynthesis of thyroid hormone in vertebrates, and there is evidence fo

183 Thus, developmental levels of thyroid hormone influence the epigenetic information of

184 PFHxS lowered thyroid hormone levels in both dams and offspring in a d

185 , internal chemical dosimetry, and placental thyroid hormone levels were determined.

186 neral term for excess circulating and tissue thyroid hormone levels, whereas hyperthyroidism specific

187 anges in food intake, physical activity, and thyroid hormone levels.

188 or roles in cellular antioxidant defense and thyroid hormone metabolism.

189 suggesting comparable epigenetic effects of thyroid hormone on both the male and female ancestral ge

190 yroid hormone triiodothyronine and synthetic thyroid hormone receptor agonists, such as sobetirome (G

191 In the retina, thyroid hormone receptor beta (thrb) is required for exp

192 a (PPARG), glucocorticoid receptor (GR), and thyroid hormone receptor beta (THRB), when exposed to 14

193 ated that PI3K/Akt signaling is important in thyroid hormone receptor beta(PV/PV) knock-in (PV) mice

194 is suboptimal because of lower expression of thyroid hormone receptor beta.

195 CIP4 (Cdc42-interacting protein 4)/TRIP10 (thyroid hormone receptor interactor 10) was identified a

196 a status that is readily treatable with oral thyroid hormone replacement therapy.

197 R) that act as agonists and induce excessive thyroid hormone secretion, releasing the thyroid gland f

198 ell decisions in the retinal tissue based on thyroid hormone signaling activity.

199 Thus, chemicals that can affect thyroid hormone signaling during pregnancy are of great

200 Thyroid hormone signaling plays a critical role in activ

201 luate the potential contribution of aberrant thyroid hormone status to the epigenetic inheritance of

202 pollutants are known to adversely affect the thyroid hormone system, and major gaps have been identif

203 rocarbon receptor activity or binding to the thyroid hormone transport protein was found.

204 Thyroid hormone triiodothyronine and synthetic thyroid h

205 brain-based markers or measurable metrics of thyroid hormone-dependent perturbations in brain develop

206 No evidence of thyroid hormone-mediated neurobehavioral disruption in o

207 CoR1) and silencing mediator for retinoid or thyroid-hormone receptors (SMRT) are the best characteri

208 fepristone, the HPT axis-based treatments of thyroid hormones (T(3) and T(4)), and the HPG axis-based

209 ogical treatments to highlight the role that thyroid hormones (TH) play in sensory development and de

210 efore studied whether maternally transferred thyroid hormones (THs) exert context-dependent effects o

211 Thyroid hormones are critical for mammalian brain develo

212 Thyroid hormones are known regulators of adult metabolis

213 lipin expression or FAO stimulation; rather, thyroid hormones are likely to negatively regulate both

214 he perinatal period and examined the role of thyroid hormones in these processes.

215 yroglobulin (TG) is the protein precursor of thyroid hormones, which are essential for growth, develo

216 ver the perinatal period and is dependent on thyroid hormones, with potential consequences for neonat

217 understand the production and regulation of thyroid hormones.

218 uitary-adrenal (HPA), hypothalamic-pituitary thyroid (HPT), and hypothalamic-pituitary-gonadal (HPG)

219 spite effective clutter filtering, motion in thyroid imaging can impact coherent integration of the D

220 ound The American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) is a

221 of the current American College of Radiology Thyroid Imaging Reporting and Data System criteria for m

222 lung cancer might result in the discovery of thyroid incidentalomas.

223 I, which showed 136% +/- 88 higher uptake in thyroid lesions (P = .02) compared with lung lesions.

224 patients with thyroid surgery (total of 414 thyroid lobectomies) were collected.

225 Of the 414 operated thyroid lobes, 2.4% (n = 10) bled.

226 omy, parathyroidectomy, neck dissections for thyroid malignancy, and adrenalectomy from 2008 to 2017.

227 Each thyroid mesenchymal tumour is characterised by its uniqu

228 omprehensive guidelines on the management of thyroid mesenchymal tumours are currently lacking.

229 Benign thyroid mesenchymal tumours have excellent prognosis, wh

230 prognosis, whereas the outcome of malignant thyroid mesenchymal tumours is variable.

231 A vast majority of thyroid mesenchymal tumours occur between the fourth and

232 he rarity and aggressive nature of malignant thyroid mesenchymal tumours, a multidisciplinary team-ba

233 Review, we provide a detailed description of thyroid mesenchymal tumours, their clinical characterist

234 djuvant chemoradiotherapy used for malignant thyroid mesenchymal tumours.

235 They are likely to develop from papillary thyroid microcarcinomas (PTMCs), found in up to 36% of h

236 rotid artery, we hypothesize that imaging of thyroid microvessels may be more reliable in the longitu

237 edly increased RAI uptake in mouse and human thyroid models.

238 Thyroid motion was tracked using 2D normalized cross-cor

239 breast (n = 16 [37%]), kidney (n = 3 [8%]), thyroid (n = 2 [6%]), and other sites (n = 5 [10%]).

240 for follicular carcinoma in Bethesda type IV thyroid nodules but their absence does not allow to pred

241 Thyroid nodules frequently require ultrasound and Fine N

242 RADS) is a recognized tool for management of thyroid nodules in adults but has not been validated in

243 s In this retrospective study, a database of thyroid nodules in patients younger than 19 years who un

244 a for guiding decisions on whether to biopsy thyroid nodules in pediatric patients in a single referr

245 Core-needle biopsy of thyroid nodules is effective because it diagnoses more t

246 System criteria for management of pediatric thyroid nodules is inadequate because a high percentage

247 life, presenting as progressively enlarging thyroid nodules that often yield non-diagnostic results

248 In these 314 patients, 404 thyroid nodules were scored, of which 19.1% (77 of 404)

249 (US) is the method of choice for evaluating thyroid nodules.

250 Over 100,000 thyroid operations are performed annually in the United

251 Over 100,000 thyroid operations are performed annually in the US.

252 d there was no increased accumulation in the thyroid or stomach.

253 Patients with melanoma, thyroid, or colorectal cancer were excluded; patients wi

254 ed through Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery and the Swedish

255 pothesis on 48 acquisitions obtained from 24 thyroid patients having at least one suspicious nodule.

256 ed for anti-thyroglobulin (anti-TG) and anti-thyroid peroxidase (anti-TPO) as models.

257 iiodothyronine (fT3, TT3), and autoimmunity [thyroid peroxidase and thyroglobulin antibodies (TPOAb a

258 ation is widely used by clinicians for other thyroid phenotypes.

259 nsports I(-) (stoichiometry 2Na(+):1I(-)) in thyroid physiology and radioiodide-based thyroid cancer

260 e also report tentative associations between thyroid receptor antagonism, chemical concentrations, an

261 higher scores indicate more symptoms) on the Thyroid-Related Quality-of-Life Patient-Reported Outcome

262 In the LDCT arm, 205 AADs (7.0%) were thyroid-related.

263 Microarray of thyroid RNA displayed incomplete overlap between the Akt

264 Thyroid scintigraphy with either radioiodine or (99m)Tc-

265 Over 12 months, thyroid size was reduced for the Akt null crosses (p < 0

266 neurons is involved in the regulation of the thyroid, somatotropic and adrenal endocrine axes, possib

267 alling are similar to the effects of altered thyroid status and mutations affecting thyroid hormone a

268 We included prospective cohorts with data on thyroid status at baseline and depressive symptoms durin

269 Neither catecholamines nor thyroid-stimulating hormone (TSH) are responsible for sa

270 Serum thyroid-stimulating hormone (TSH) measurement is the bes

271 GD is caused by autoantibodies against the thyroid-stimulating hormone (TSH) receptor.

272 rometry, and biomarkers of thyroid function [thyroid-stimulating hormone (TSH), free and total thyrox

273 ), and between anti-Dechlorane Plus (DP) and thyroid-stimulating hormone (TSH).

274 iodine supplementation on maternal or infant thyroid-stimulating hormone and free thyroxine.

275 hyroidism is caused by autoantibodies to the thyroid-stimulating hormone receptor (TSHR) that act as

276 at the luteinizing hormone receptor and the thyroid-stimulating hormone receptor (TSHR), stimulation

277 nts in the metabolic radiotherapy unit after thyroid stimulation.

278 sis and Graves' disease represented the main thyroid storm etiologies (30 [33%] and 24 [26%] patients

279 val rates of patients with those most severe thyroid storm forms requiring ICU admission.

280 Thyroid storm represents a rare but life-threatening end

281 Thyroid storm requiring ICU admission causes high in-ICU

282 Inclusion criteria were "definite thyroid storm," as defined by the Japanese Thyroid Assoc

283 yroid Association criteria, and at least one thyroid storm-related organ failure.

284 scans by 60%, myocardial studies by 66%, and thyroid studies by 67%.

285 trospective study, data of 279 patients with thyroid surgery (total of 414 thyroid lobectomies) were

286 atients (51 women and 10 men) that underwent thyroid surgery and had histopathological results of eit

287 but rarely life-threatening complications in thyroid surgery.

288 Here, we investigated its effects on the thyroid system and neurodevelopment following maternal e

289 association between helper T cell content in thyroid tissue and a COMMD3/DNAJC1 regulatory variant (P

290 ed proliferation, invasion, and migration in thyroid tumor cell models.

291 We confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has we

292 wed 136% +/- 88 greater uptake in orthotopic thyroid tumors compared with pulmonary lesions, which re

293 Results TAM levels were higher in orthotopic thyroid tumors compared with pulmonary metastatic lesion

294 e tumor suppressor miR-200b is overedited in thyroid tumors, and its levels of editing correlate with

295 function and growth of malignant and benign thyroid tumors.

296 Most primary thyroid tumours are of epithelial origin.

297 nsemble cross-correlation coefficient of the thyroid ultrasound images were significantly higher (p <

298 ented or diminished the increase in maternal thyroid volume during pregnancy.

299 Dosimetric estimates based on the thyroid volume to be treated and on radioiodine uptake s

300 In each patient, ultrasound images of the thyroid were acquired in both longitudinal and transvers